Adding Epcoritamab to R-CHOP Cut Lymphoma Progression or Death Risk by 51% in Topline Phase 3 Trial Results

Topline phase 3 data show epcoritamab plus R-CHOP cut progression or death risk by 51% in newly diagnosed DLBCL. Results are not yet peer-reviewed.

Have A Referral?